<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373701">
  <stage>Registered</stage>
  <submitdate>22/09/2017</submitdate>
  <approvaldate>4/10/2017</approvaldate>
  <actrnumber>ACTRN12617001402336</actrnumber>
  <trial_identification>
    <studytitle>Cytokine response in the pleural fluid and blood in minimal-invasive and open esophagectomy</studytitle>
    <scientifictitle>Cytokine response in the pleural fluid and blood in minimal-invasive and open esophagectomy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>oesophageal cancer
</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Oesophageal (gullet)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Open esophagectomy. Informed consent is provided describing risk and benefits of the procedure. All open procedures are performed by experienced oesophageal and upper GI surgeons. The Duration of the procedure is 120-240 minutes. Patients are surveilled on the intensive care unit postoperatively. Open esophagectomy involves thoracotomy and laparotomy. After esophageal resection, reconstruction and anastomosis is performed using the remnant stomach.</interventions>
    <comparator>Minimal invasive (laparoscopic and thoracosopic) esophagecotmy. Informed consent is provided describing risk and benefits of the procedure. All minimal invasive  procedures are performed by experienced oesophageal and upper GI surgeons. The Duration of the procedure is 120-240 minutes. Esophagectomy and Reconstruction are performed with minimal invasive approach such as laparoscopic and thoracoscopic. Patients are surveilled on the intensive care unit postoperatively. 


 </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite Primary outcome: cytokine Response (IL)-6 and IL-8, the anti-inflammatory IL-1 RA and the chemokines CINC-1 and MCP-1.Blood specimens were collected from intravenous or arterial lines that were routinely in place. Concentrations of IL-6, IL-8, IL-1RA, CINC-1 and MCP-1 in the blood and the collected pleural fluid were analyzed using enzyme-linked immune-sorbent assays (ELISA, R &amp; D Systems, Minneapolis, MN, USA). </outcome>
      <timepoint>Baseline, end of surgery, 24 hours (Primary outcome), 48 hours and 72 hours postoperatively. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>complications such as leaks, abscess, cardiac or pulmonary complications. clinical and Imaging assessemnt</outcome>
      <timepoint>early postoperative phase (1 to 29 days postoperatively)  and late postoperative phase(30 days to last clinical consult 1 year postoperatively), </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients eligible for Operation, oesphageal cancer requiring surgery, aged over 18 years, able to sign in for informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>not fit for operation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence>n/a</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures>The allocation was not randomized, but followed the individual surgeons preference for one or the other technique.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>prospective inclusion of 12 patients per Group, no power calculation</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/09/2012</actualenddate>
    <samplesize>24</samplesize>
    <actualsamplesize>24</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Flinders Medical Centre</primarysponsorname>
    <primarysponsoraddress>Bedford Park SA 5042, Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Flinders Medical Centre</fundingname>
      <fundingaddress>Bedford Park, SA 5042, Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To investigate cytokine Response in the blood and pleural fluid in laparoscopic versus open esophagectomy in esophageal cancer. Prospective non randomised Trial. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>FLINDERS CLINICAL RESEARCH ETHICS COMMITTEE</ethicname>
      <ethicaddress>Southern Adelaide Clinical Human Research Ethics Committee, Flinders Dr1, Bedford Park SA 5042, Australia</ethicaddress>
      <ethicapprovaldate>31/12/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Mr</title>
      <name>Urs Zingg</name>
      <address>Spital Limmattal, PD Dr. med. Urs Zingg, Urdorferstrasse 38. 8952 Schlieren, Switzerland</address>
      <phone>+41 44 733 24 05 </phone>
      <fax />
      <email>Sekretariat.chirurgie@spital-limmattal.ch</email>
      <country>Switzerland</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Tarik Delko</name>
      <address>Unispital Basel, Spitalstrassse 21, 4031 Basel, Switzerland</address>
      <phone>+41 76 910 30 21</phone>
      <fax />
      <email>tarik.delko@usb.ch</email>
      <country>Switzerland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>tarik delko</name>
      <address>Unispital Basel, spitalstrasse 21, 4031 Basel, Switzerland, </address>
      <phone>+41 76 910 30 21</phone>
      <fax />
      <email>tarik.delko@usb.ch</email>
      <country>Switzerland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>